Active Ingredient(s): Ceftazidime + Avibactam
FDA Approved: * February 25, 2015
Pharm Company: * CEREXA
Category: Antibiotics

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Avycaz Overview

Avibactam is a non-β-lactam β-lactamase inhibitor[2] developed by Actavis (now Teva) jointly with AstraZeneca. A new drug application for avibactam in combination with ceftazidime (branded as Avycaz) was approved by the FDA on February 25, 2015, for treating complicated urinary tract (cUTI) and complicated intra-abdominal infections (cIAI) caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant Gram-negative bacterial pathogens.&#...

Read more Avycaz Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Avibactam

Recent Avycaz Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ceftazidime + Avibactam
  • Injection: 2g + 0.5g
  • Powder: 0.5gm + 2gm/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Avycaz: (1 result)

Sorted by National Drug Code
  • 0456-2700 Avycaz Intravenous Powder, for Solution by Forest Laboratories, Inc.

Drugs with one or more similar ingredients: (6 results)